60
Participants
Start Date
July 27, 2020
Primary Completion Date
November 30, 2025
Study Completion Date
November 30, 2025
Olaparib
Olaparib 300mg twice daily, oral medication administered for at least 2 weeks and up until the morning of nephrectomy. Arms 2, 3 and 5
Cediranib
Cediranib 20mg once daily, oral medication administered for at least 2 weeks until 36 hours prior to nephrectomy. Arms 1 and 3
Durvalumab
Durvalumab 1500mg intravenous infusion administered once, no greater than 4 weeks prior to nephrectomy
RECRUITING
Addenbrooke's Hospital, Cambridge
RECRUITING
Beatson Institute for Cancer Research, Glasgow
Collaborators (2)
University of Cambridge
OTHER
AstraZeneca
INDUSTRY
Cancer Research UK
OTHER
CCTU- Cancer Theme
OTHER